C. Ola Landgren (IMAGE)

University of Miami Miller School of Medicine

C. Ola Landgren

Caption

“We found a strong correlation between sustained MRD negativity and prolonged survival,” said C. Ola Landgren, MD, PhD, chief of the Division of Myeloma at Sylvester. “In fact, patients who were treated with modern combination therapy and achieved and sustained MRD negativity for at least two years were highly likely to remain free from multiple myeloma 10 years later.”

Credit

Photo by Sylvester

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.